Discover how botanical and nutrient therapies provided adjunctive support for a 76-year-old patient with treatment-resistant paroxysmal atrial fibrillation. This case study highlights integrative ...

The company is currently undertaking its Vision-MR Ablation of Atrial Flutter (VISABL-AFL) pivotal clinical trial supporting US FDA approval of its products, which it hopes to achieve in 2025.

1 Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada Introduction Atrial fibrillation (AF) affects 10% of patients undergoing cardiac surgery and is an independent ...

Imricor Medical Systems has announced another key milestone towards US regulatory approval for its devices with submission of ...

The diagnosis of AF was based on the presence of atrial flutter or AF on ECGs from Framingham clinic visits, outside physician or hospital charts, or Holter reports adjudicated by at least two ...

Radiofrequency ablation (RFA) is an important therapeutic modality for atrial fibrillation ... chest CT suggested possible air accumulation in the left atrial region. ECG findings were consistent with ...

Linear ablation combined with ethanol infusion of the EIVOM provided additional benefit ... Additionally, 13.8% of patients in the intervention group compared with 17.3% of patients in the PVI alone ...

Many people with atrial flutter have a heart rate of around 150 bpm. Atrial flutter is often definitively treated with cardiac ablation. These arrhythmias involve abnormalities in the heart's ...

Original Medicare and Medicare Advantage should cover most atrial fibrillation (A-fib ... such as catheter or surgical ablation, pacemaker implantation, or electrical cardioversion.

for the treatment of type 1 atrial flutter (AF). Imricor Medical Systems’ (ASX:IMR) second-generation Vision-MR Ablation Catheter is the device involved in the company’s pivotal VISABL-AFL ...